High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms |
Type de publication | Journal Article |
Year of Publication | 2015 |
Auteurs | Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J, Girodon F, Andreasson B |
Journal | EUROPEAN JOURNAL OF INTERNAL MEDICINE |
Volume | 26 |
Pagination | 344-347 |
Date Published | JUN |
Type of Article | Article |
ISSN | 0953-6205 |
Mots-clés | Essential thrombocythemia, Myelofibrosis, myeloproliferative neoplasm, polycythemia vera, vascular complications |
Résumé | Background: Vascular complications occurring before the diagnosis of myeloproliferative neoplasms (MPN) in 612 patients from four centers in Sweden, Denmark and France were retrospectively studied. Results: Vascular complications were observed in 151 (25%) of the 612 patients. Of these, 66% occurred during the two years preceding diagnosis. The majority of events were thromboembolic (95%), and included myocardial infarction (n = 46), ischemic stroke (n = 43), transient ischemic attack (TIA) (n = 22), deep vein thrombosis/pulmonary embolism (n= 19), splanchnic vein thrombosis (n= 7), and peripheral embolism (n= 7). Bleeding was observed in only 7 (5%) of the 151 patients with vascular events (3 with intracranial bleeding, 2 with epistaxis and 2 with gastrointestinal bleeding). Full blood counts obtained at least 3 months prior to the MPN diagnosis showed that 269 (44%) had abnormal blood values, fulfilling the diagnostic criteria for MPN. During the time from the abnormal blood test to the diagnosis of MPN, 50 patients suffered from a vascular complication. Conclusion: We therefore conclude that a large proportion of MPN patients suffer severe thromboembolic complications prior to diagnosis. If MPN were diagnosed earlier, a large proportion of these events might be prevented. An MPN should always be suspected and ruled out in patients with unexplained elevated hematocrit, leukocyte and/or platelet counts. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. |
DOI | 10.1016/j.ejim.2015.03.009 |